Inozyme Pharma FY 2024 GAAP EPS $(1.62) Misses $(1.60) Estimate; Co. Prioritizes Activities To Support Planned Biologics License Application Filing For INZ-701 In ENPP1 Deficiency, Announces 25% Workforce Reduction

Benzinga03-10

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2518022528?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-10 20:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2518022528","market":"us","top_or_hot":-1,"title":"Inozyme Pharma FY 2024 GAAP EPS $(1.62) Misses $(1.60) Estimate; Co. Prioritizes Activities To Support Planned Biologics License Application Filing For INZ-701 In ENPP1 Deficiency, Announces 25% Workforce Reduction","media":"Benzinga","content":"<html><body><p><a href=\"https://laohu8.com/S/INZY\">Inozyme Pharma</a> FY 2024 GAAP EPS $(1.62) Misses $(1.60) Estimate; Co. Prioritizes Activities To Support Planned Biologics License Application Filing For INZ-701 In ENPP1 Deficiency, Announces 25% Workforce Reduction</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inozyme Pharma FY 2024 GAAP EPS $(1.62) Misses $(1.60) Estimate; Co. Prioritizes Activities To Support Planned Biologics License Application Filing For INZ-701 In ENPP1 Deficiency, Announces 25% Workforce Reduction</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInozyme Pharma FY 2024 GAAP EPS $(1.62) Misses $(1.60) Estimate; Co. Prioritizes Activities To Support Planned Biologics License Application Filing For INZ-701 In ENPP1 Deficiency, Announces 25% Workforce Reduction\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2025-03-10 20:36</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><a href=\"https://laohu8.com/S/INZY\">Inozyme Pharma</a> FY 2024 GAAP EPS $(1.62) Misses $(1.60) Estimate; Co. Prioritizes Activities To Support Planned Biologics License Application Filing For INZ-701 In ENPP1 Deficiency, Announces 25% Workforce Reduction</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INZY","symbol_name":"Inozyme Pharma","start_time":0,"source_url":"https://www.benzinga.com/general/biotech/25/03/44217803/inozyme-pharma-fy-2024-gaap-eps-1-62-misses-1-60-estimate-co-prioritizes-activities-to-support-pl","article_id":"2518022528","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518022528","pubTimestamp":1741610169,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Inozyme Pharma FY 2024 GAAP EPS $(1.62) Misses $(1.60) Estimate; Co. Prioritizes Activities To Support Planned Biologics License Application Filing For INZ-701 In ENPP1 Deficiency, Announces 25% Workforce Reduction","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"INZY":"Inozyme Pharma"},"translate_title":"Inozyme Pharma 2024财年GAAP EPS$(1.62)低于$(1.60)预期；Co.优先开展活动，支持INZ-701因ENPP1缺乏症而计划提交的生物制品许可证申请，并宣布裁员25%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INZY":1},"content_text":"Inozyme Pharma FY 2024 GAAP EPS $(1.62) Misses $(1.60) Estimate; Co. Prioritizes Activities To Support Planned Biologics License Application Filing For INZ-701 In ENPP1 Deficiency, Announces 25% Workforce Reduction","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2518022528","isCrawlerRequest":true}